Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants With Major Depressive Disorder
Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants With Major Depressive Disorder
This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy and safety of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), and complete the 6 weeks double-blind treatment, provide informed consent, and meet eligibility criteria, may enter this extension study.
Key Inclusion Criteria:
Rollover participants are eligible for the study if the following inclusion criteria are met:
Key Exclusion Criteria:
Rollover participants are excluded from the study if any of the following exclusion criteria are met:
Botafogo - Rio de Janeiro, Rio de Janeiro 22270-060, Brazil
Varosha, Targovishte 7700, Bulgaria
Białystok, Podkarpackie Voivodeship 15-879, Poland